title: High affinity binding of epibatidine to serotonin type 3 receptors.
abstract: Epibatidine and mecamylamine are ligands used widely in the study of nicotinic acetylcholine receptors (nAChRs) in the central and peripheral nervous systems. In the present study, we find that nicotine blocks only 75% of (125)I-epibatidine binding to rat brain membranes, whereas ligands specific for serotonin type 3 receptors (5-HT(3)Rs) block the remaining 25%. (125)I-Epibatidine binds with a high affinity to native 5-HT(3)Rs of N1E-115 cells and to receptors composed of only 5-HT(3A) subunits expressed in HEK cells. In these cells, serotonin, the 5-HT(3)R-specific antagonist MDL72222, and the 5-HT(3)R agonist chlorophenylbiguanide readily competed with (125)I-epibatidine binding to 5-HT(3)Rs. Nicotine was a poor competitor for (125)I-epibatidine binding to 5-HT(3)Rs. However, the noncompetitive nAChR antagonist mecamylamine acted as a potent competitive inhibitor of (125)I-epibatidine binding to 5-HT(3)Rs. Epibatidine inhibited serotonin-induced currents mediated by endogenous 5-HT(3)Rs in neuroblastoma cell lines and 5-HT(3A)Rs expressed in HEK cells in a competitive manner. Our results demonstrate that 5-HT(3)Rs are previously uncharacterized high affinity epibatidine binding sites in the brain and indicate that epibatidine and mecamylamine act as 5-HT(3)R antagonists. Previous studies that depended on epibatidine and mecamylamine as nAChR-specific ligands, in particular studies of analgesic properties of epibatidine, may need to be reinterpreted with respect to the potential role of 5-HT(3)Rs.
authors: Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA.
authors: Renaldo C
authors: RC
authors: Drisdel
authors: Douglas
authors: D
authors: Sharp
authors: Tricia
authors: T
authors: Henderson
authors: Tim G
authors: TG
authors: Hales
authors: William N
authors: WN
authors: Green
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006801:Humans; D008464:Mecamylamine / Q000494:pharmacology; D051379:Mice; D009538:Nicotine / Q000378:metabolism / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011485:Protein Binding; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism; D044406:Receptors, Serotonin, 5-HT3 / Q000235:genetics / Q000378:metabolism; D058831:Serotonin 5-HT3 Receptor Antagonists
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011725:Pyridines; D011978:Receptors, Nicotinic; D044406:Receptors, Serotonin, 5-HT3; D058831:Serotonin 5-HT3 Receptor Antagonists; D008464:Mecamylamine; D009538:Nicotine; C082748:epibatidine
references: Brain Res Mol Brain Res. 1994 Oct;26(1-2):233-41
references: 7854052
references: Neurosci Lett. 1998 May 15;247(2-3):107-10
references: 9655604
references: J Neurosci. 2002 Feb 1;22(3):1010-9
references: 11826129
references: Psychopharmacology (Berl). 2006 Mar;184(3-4):314-27
references: 16001112
references: Scand J Rheumatol Suppl. 2004;119:2-8
references: 15515404
references: Pain. 1999 Mar;80(1-2):291-9
references: 10204742
references: J Pharmacol Exp Ther. 1996 Feb;276(2):509-15
references: 8632316
references: J Pharmacol Exp Ther. 1995 Mar;272(3):1199-203
references: 7891333
references: J Neurosci. 2002 Sep 1;22(17):7389-97
references: 12196560
references: J Pharmacol Exp Ther. 2001 Dec;299(3):1112-9
references: 11714901
references: J Pharmacol Exp Ther. 2005 Apr;313(1):389-94
references: 15608080
references: J Med Chem. 1998 Feb 12;41(4):407-12
references: 9484491
references: Brain Res. 1997 Jan 30;747(1):1-8
references: 9042521
references: Methods Enzymol. 1998;293:564-85
references: 9711629
references: Neuropharmacology. 2003 Feb;44(2):214-23
references: 12623220
references: Annu Rev Pharmacol Toxicol. 2007;47:699-729
references: 17009926
references: J Pharmacol Exp Ther. 2000 Apr;293(1):67-74
references: 10734154
references: Br J Pharmacol. 1989 May;97(1):27-40
references: 2720311
references: Neuropharmacology. 1997 Aug;36(8):1119-25
references: 9294978
references: Neuropharmacology. 1998 Dec;37(12):1515-25
references: 9886674
references: J Pharmacol Exp Ther. 1993 Jun;265(3):1511-8
references: 8099622
references: Neuropharmacology. 2000 Oct;39(13):2561-9
references: 11044727
references: Indian J Exp Biol. 2004 Apr;42(4):368-72
references: 15088686
references: Biochem Soc Trans. 2004 Jun;32(Pt3):529-34
references: 15157178
references: Neurosci Lett. 1996 Apr 26;208(3):203-7
references: 8733305
references: Science. 1991 Oct 18;254(5030):432-7
references: 1718042
references: Trends Neurosci. 1995 Mar;18(3):121-7
references: 7754520
references: J Pharmacol Exp Ther. 2004 Feb;308(2):591-9
references: 14610221
references: Bioorg Med Chem Lett. 2001 Feb 12;11(3):319-21
references: 11212100
references: Neuroreport. 1995 Jul 10;6(10):1464-8
references: 7488749
references: Neuropharmacology. 2002 Dec;43(7):1070-6
references: 12504912
references: Brain Res. 2004 Nov 26;1028(1):48-58
references: 15518641
references: Eur J Pharmacol. 2002 Oct 4;452(2):137-44
references: 12354563
references: Trends Pharmacol Sci. 2000 Jun;21(6):211-7
references: 10838608
references: J Pharmacol Exp Ther. 1993 May;265(2):777-89
references: 8388459
references: J Pharmacol Exp Ther. 1978 Sep;206(3):644-51
references: 702327
references: Neuroreport. 1999 Jun 3;10(8):1631-6
references: 10501548
references: J Neurochem. 2003 Jun;85(5):1237-46
references: 12753083
references: BMC Neurosci. 2006 Mar 29;7:27
references: 16571125
references: Pain. 2001 Jan;89(2-3):159-65
references: 11166471
references: Brain Res. 1997 Jun 13;759(2):313-6
references: 9221955
references: J Pharmacol Exp Ther. 1994 Nov;271(2):624-31
references: 7965777
references: Exp Biol Med (Maywood). 2001 Dec;226(11):1024-30
references: 11743138
references: Mol Pharmacol. 1995 Oct;48(4):774-82
references: 7476906
references: Br J Pharmacol. 1995 Jul;115(6):953-60
references: 7582526
references: J Pharmacol Exp Ther. 1995 Aug;274(2):771-82
references: 7543571
references: Pain. 2000 Apr;85(3):443-450
references: 10781917
references: J Appl Physiol (1985). 2002 Jun;92(6):2529-34
references: 12015369
references: J Pharmacol Exp Ther. 1998 Dec;287(3):847-53
references: 9864263
references: Alcohol Clin Exp Res. 1994 Apr;18(2):410-4
references: 8048747
references: Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):27-37
references: 14965242
references: Eur J Neurosci. 2005 Jun;21(11):3182-8
references: 15978026
references: Eur J Pharmacol. 1990 Sep 18;189(2-3):223-7
references: 2253704
references: J Neurosci. 1991 Jul;11(7):1881-8
references: 2066767
references: Br J Pharmacol. 2000 Oct;131(4):729-39
references: 11030722
references: J Neurosci. 1998 Jul 15;18(14):5426-32
references: 9651224
references: Pain. 2006 Nov;125(1-2):125-35
references: 16781069
references: J Cardiovasc Pharmacol. 1990;15 Suppl 7:S17-34
references: 1702484
references: J Pharmacol Exp Ther. 1994 Aug;270(2):702-7
references: 8071862
references: Clin Ther. 2001 Apr;23(4):532-65
references: 11354389
references: Pharmacol Rev. 1996 Jun;48(2):179-211
references: 8804103
references: Mol Pharmacol. 1999 Jun;55(6):1037-43
references: 10347245
references: Neuropharmacology. 1994 Mar-Apr;33(3-4):493-9
references: 7984288
references: Brain Res. 2002 Oct 25;953(1-2):53-62
references: 12384238
references: Mol Pharmacol. 2006 Sep;70(3):947-59
references: 16728647
references: Mol Pharmacol. 1994 Apr;45(4):563-9
references: 8183234
references: Mol Pharmacol. 2004 Mar;65(3):611-22
references: 14978239
references: Brain Res. 1994 Nov 21;664(1-2):34-40
references: 7895043
references: Mol Pharmacol. 1995 Aug;48(2):280-7
references: 7651361
references: J Neurosci. 2000 Jan 1;20(1):133-9
references: 10627589
references: Brain Res Bull. 2004 Dec 15;64(4):323-30
references: 15561467
references: J Physiol Paris. 1998 Jun-Aug;92(3-4):221-4
references: 9789812
references: J Pharmacol Exp Ther. 2003 Sep;306(3):1159-66
references: 12829730